Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
Open Access
- 1 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 36 (9) , 1717-1728
Abstract
A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs). We attempted to identify the risk factors for these VF and to examine the protective role of bisphosphonates. For that, 22 specialists in Switzerland provided data of unselected patients, treated with denosumab for osteoporosis or breast cancer without metastases under aromatase inhibitors, who have received at least two injections of Dmab, with at least 1 year of follow-up after discontinuation. The questionnaire covered separately the periods before, during, and after Dmab treatment, and registered clinical, radiological, and lab data. For the analysis of the risk factors, the main outcomes were the time to the first VF after the treatment, the presence of multiple VFs (MVFs), and the number of VFs. The incidence of VF was 16.4% before, 2.2% during, and 10.3% after the treatment with Dmab. The risk of VF after Dmab discontinuation was associated with an increased risk of non-vertebral fractures. The pretreatment predictors of the post-treatment fracture risk were a parental hip fracture and previous VFs. Further risk factors appeared later, such as low total hip bone mineral density (BMD) during and after denosumab, increased bone resorption markers, and the loss of total hip BMD after the denosumab. Treatment with bisphosphonates, especially after Dmab, had a protective effect. Bisphosphonates given before Dmab did not further decrease the risk of VF in cases who got bisphosphonates after Dmab. This study shows that the risk of VF is poorly predictable before the prescription of denosumab. But during and after the treatment, bone resorption markers and BMD have a significant predictive value. Bisphosphonates after the treatment with denosumab are protective against VFs. © 2021 American Society for Bone and Mineral Research. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).Keywords
This publication has 33 references indexed in Scilit:
- Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases ReportThe Journal of Clinical Endocrinology & Metabolism, 2016
- Clinical vertebral fractures following denosumab discontinuationEndocrine, 2016
- Multiple clinical vertebral fractures following denosumab discontinuationOsteoporosis International, 2015
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanicsOsteoporosis International, 2015
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reportsOsteoporosis International, 2015
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) TrialJournal of Bone and Mineral Research, 2012
- Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy studyJournal of Bone and Mineral Research, 2011
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone MassThe Journal of Clinical Endocrinology & Metabolism, 2011
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 1993